nanosurface 2006-12-09 03:00
纳囊, Nanocapsules
[quote]
^nL"X3Jyz5m
是指粒径以纳米单位衡量的微囊,兼有微囊和纳米粒子的优点,作为载药纳囊,不但可起到所载药物免受外界环境影响,而且在受体环境释放时,可以控制所载药物的释放。另一方面,其尺寸效应导致其明显的表面效应,显示出材料亲和性好,生物相容性好,受体的聚积性,在生物体内易吸收,易利用等。应用纳米药囊技术,药物在很大程度上可以与受体增加有效接触面积,药物的药效也将随药物的纳囊尺寸效应而显著提高。此外,纳米药囊还可以使药物针对其病灶集中或控制地释放,在提高药物利用率的同时,避免了药物对人体其他部位的不良刺激,更有利于降低药物的毒副作用。
k3DrT
FgJ6Ei8d
[/quote]
K7D8k5aJE+aQ
+F"Y}9jf
[quote]
Z-X4r$Lc
Conceptually, the ideal case for optimal activity would be to entrap the ODNs within the internal core of polymeric nanocapsules in order to mask them and to prevent them from any interaction with proteins. In the state of the art, all the methodologies available to prepare nanocapsules involve the preparation of emulsions, either O/W emulsions which lead to nanocapsules with an oily core suspended in water (Al Khouri process) or W/O emulsions which lead to nanocapsules with an aqueous core suspended in oil (Vranckx). Oily nanocapsules are unable to encapsulate the water soluble ODNs and aqueous nanocapsules in an oily phase are not compatible with the conditions for i.v. administration. This is the reason why, in this study, we have developed a new process of preparation of aqueous nanocapsules containing ODNs which were successfully suspended in a water medium. We have localized the ODNs in the core of these nanocapsules which explains why this carrier is providing a high protection of ODNs against enzymatic degradation.
1qPL(`(i3{z&\5H
[url=http://imageshack.us][img]http://img297.imageshack.us/img297/9254/nanoca2qg5.jpg[/img][/url]-`(v!O#cGp
[/quote];\1}t+^6Q)]
@J.mA#V({'c
[font=Arial][font=Arial,Helvetica,sans-serif][size=4][color=#990000][b]References
"|w*A1E#wy*y
p|
k[5CEI8n0]
[/b][/color][/size][/font][/font][align=left][font=Arial][b][font=Arial][size=10pt]Lambert[/size][/font][/b][font=Arial][size=10pt][b] G.[/b], Bertrand J.R. , Fattal E., Pinto-Alphandary H., Malvy C., Auclair C. and Couvreur P., EWS-Fli1 Antisense Nanocapsules Inhibits Ewing Sarcoma related Tumor in Mice. [i]Biochemical and Biophysical Research Communication. [/i]279(2): 401-6 (2000).[i] [/i][/size][/font][/font][/align][font=Arial] [/font][align=left][font=Arial][b][font=Arial][size=10pt]Lambert[/size][/font][/b][font=Arial][size=10pt][b] G.[/b], Fattal E., Pinto-Alphandary H., Gulik A. and Couvreur P., Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. [i]Pharmaceutical Research[/i], 17: 707-714 (2000). [/size][/font][/font][/align][font=Arial] [/font][align=left][font=Arial][b][font=Arial][size=10pt]Lambert G.[/size][/font][/b][font=Arial][size=10pt], Fattal E., Pinto-Alphandary H., Gulik A. and Couvreur P., Polyisobutylcyanoacrylate nanocapsules containing an aqueous core for the delivery of oligonucleotides. [i]International Journal of Pharmaceutics. [/i]214(1-2): 13-6 (2000). [/size][/font][/font][/align][font=Arial] [/font][align=left][font=Arial][b][font=Arial][size=10pt]Lambert G.[/size][/font][/b][font=Arial][size=10pt], Fattal E. and Couvreur P.. Nanoparticulate systems for the delivery of antisense oligonucleotides. [i]Advanced Drug Delivery Reviews[/i]. 47(1): 99-112 (2000). [/size][/font][/font][/align][font=Arial] [/font][align=left][font=Arial][size=2][b]Lambert, G.[/b], Fattal, E., Brehier, A., Feger, J., Couvreur, P., (1998), Effect of polyisobutylcyanoacrylate nanoparticles and Lipofectin loaded with oligonucleotides on cell viability and PKC alpha neosynthesis in HepG2 cells, Biochimie, 80, 969-976.[/size][/font][/align][align=left][font=Arial] [size=2]Maksimenko A., Malvy C., [b]Lambert G.[/b], Bertrand J.R., Fattal E. and Couvreur P., Particulate carriers are needed to inhibit tumor proliferation with antisense oligonucleotides targeted towards a junction sequence, Journal of National Cancer Institute. Submitted 2002.[/size][/font][/align][align=left][font=Arial][size=2]Fattal, E., Vauthier, C., Aynie, I., Nakada, Y., [b]Lambert, G[/b]., Malvy, C., Couvreur, P. (1998), Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides, Journal of Controlled Release, 53, 137-143.[/size][/font][/align][font=Arial] [/font][align=left][font=Arial][size=2]Dubois E. and [b]Lambert G.[/b], Les émulsions médicamenteuses administrées par voie parentérale, "Introduction aux dispositifs thérapeutiques et nouvelles formes galéniques", Editions Tec&Doc (2002).
"G ej-X6WD9U
v/\-}O;U
Garrigue J.S. and [b]Lambert G.[/b], Microémulsions et systèmes auto-émulsionnants, "Introduction aux dispositifs thérapeutiques et nouvelles formes galéniques", Editions Tec&Doc, (2002).[/size][/font][/align][font=Arial] [/font][align=left][font=Arial][size=2]Yang S., Gursoy R.N., [b]Lambert G.[/b] and Benita S., Pharmacokinetics of Paclitaxel Self-Emulsifying Drug Delivery Systems following Intravenous and Oral Administrations, Pharmaceutical Research, Submitted 2002.[/size][/font][/align][font=Arial] [/font][align=left][font=Arial][size=2]Benita S. and [b]Lambert G.[/b], Method and Composition for Dry Eye Treatment (Patent Filed November 2001). _]$hb5^